X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9) 9
article (8) 8
humans (8) 8
leukemia, lymphocytic, chronic, b-cell - drug therapy (6) 6
oncology (6) 6
survival (6) 6
aged (5) 5
btk (5) 5
female (5) 5
hematology (5) 5
ibrutinib (5) 5
male (5) 5
bone marrow (4) 4
cll (4) 4
leukemia, lymphocytic, chronic, b-cell - pathology (4) 4
middle aged (4) 4
proliferation (4) 4
pyrazoles - therapeutic use (4) 4
pyrimidines - therapeutic use (4) 4
aged, 80 and over (3) 3
animals (3) 3
bone marrow - pathology (3) 3
chronic lymphatic leukemia (3) 3
chronic lymphocytic leukemia (3) 3
leukemia, lymphocytic, chronic, b-cell - genetics (3) 3
leukemia, lymphocytic, chronic, b-cell - metabolism (3) 3
lymphatic leukemia (3) 3
rituximab (3) 3
adult (2) 2
antineoplastic agents - pharmacology (2) 2
antineoplastic agents - therapeutic use (2) 2
b-cell receptor (2) 2
cells (2) 2
chemotherapy (2) 2
chronic lymphocytic-leukemia (2) 2
clinical trials (2) 2
combination therapy (2) 2
cyclophosphamide (2) 2
disease models, animal (2) 2
drug resistance, neoplasm - genetics (2) 2
flow cytometry (2) 2
follow-up studies (2) 2
immunophenotyping (2) 2
in-vitro (2) 2
leukemia (2) 2
leukemia, lymphocytic, chronic, b-cell - blood (2) 2
lymphoma (2) 2
mice (2) 2
pci-32765 (2) 2
progression (2) 2
pyrazoles - pharmacology (2) 2
pyrimidines - pharmacology (2) 2
research (2) 2
therapeutic target (2) 2
tumor microenvironment - drug effects (2) 2
17p deletion (1) 1
abridged index medicus (1) 1
acalabrutinib (1) 1
activation (1) 1
adenosine - pharmacology (1) 1
adhesion (1) 1
agammaglobulinaemia tyrosine kinase (1) 1
agent orange (1) 1
alemtuzumab (1) 1
amino acids - metabolism (1) 1
animal models (1) 1
anti-cd20 monoclonal antibody (1) 1
antigen (1) 1
antigens, cd20 - genetics (1) 1
antigens, cd20 - metabolism (1) 1
apoptosis (1) 1
apoptosis - drug effects (1) 1
articles (1) 1
b-cell-receptor (1) 1
b-lymphocytes - drug effects (1) 1
b-lymphocytes - immunology (1) 1
b-lymphocytes - metabolism (1) 1
b-lymphocytes - pathology (1) 1
bcl-x protein (1) 1
benzamides - administration & dosage (1) 1
biochemistry & molecular biology (1) 1
biopsy (1) 1
blood cells (1) 1
blood viscosity - drug effects (1) 1
bone marrow - immunology (1) 1
bone marrow - metabolism (1) 1
brain - drug effects (1) 1
brain - metabolism (1) 1
brain slices (1) 1
bruton tyrosine kinase (1) 1
bruton's tyrosine kinase (1) 1
brutons tyrosine kinase (1) 1
btk and chronic lymphocytic leukemia (1) 1
calcium (1) 1
cancer (1) 1
cd20 (1) 1
cd52 (1) 1
cd55 antigens - genetics (1) 1
cd55 antigens - metabolism (1) 1
cell communication - drug effects (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 169 - 176
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2019, Volume 381, Issue 8, pp. 788 - 789
To the Editor: In their phase 2 study, Jain et al. (May 30 issue) 1 investigated the efficacy of ibrutinib and venetoclax in previously untreated patients with... 
MEDICINE, GENERAL & INTERNAL
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2017, Volume 23, Issue 19, pp. 5814 - 5823
Purpose: Targeting the B-cell receptor (BCR) pathway with inhibitors of Bruton tyrosine kinase (BTK) and PI3K delta is highly effective for the treatment of... 
CELLS | IBRUTINIB RESISTANCE | ONCOLOGY | IDELALISIB | COMBINATION THERAPY | RITUXIMAB | IN-VIVO | CHRONIC LYMPHOCYTIC-LEUKEMIA | LYMPHOMA | PROLIFERATION | PROGRESSION | Apoptosis - drug effects | Humans | Pyrazines - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Quinolines - pharmacology | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | Gene Expression Regulation, Neoplastic - drug effects | Class Ia Phosphatidylinositol 3-Kinase - genetics | Neoplasm Proteins - genetics | Disease Models, Animal | Tumor Microenvironment - drug effects | Adenosine - pharmacology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | B-Lymphocytes - drug effects | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Agammaglobulinaemia Tyrosine Kinase | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Spleen | Tyrosine | NF-κB protein | Therapy | Animal models | Chronic lymphatic leukemia | Cell survival | Leukemia | Lymphatic leukemia | B-cell receptor | Drug resistance | Survival | Bruton's tyrosine kinase | Mcl-1 protein | Signaling | Inhibitors | Bcl-x protein | Lymphocytes B | Experimental design | Peripheral blood | Protein-tyrosine kinase | Cancer | PI3K | BTK | CLL
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2016, Volume 22, Issue 7, pp. 1572 - 1582
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 01/2016, Volume 22, Issue 1, pp. 86 - 95
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 10/2017, Volume 58, Issue 10, pp. 2356 - 2362
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the... 
ibrutinib | CD52 | CLL | chemo-immunotherapy | SURVIVAL | CD20 | CYCLOPHOSPHAMIDE | PROLIFERATION | FLUDARABINE | TRIAL | ONCOLOGY | RITUXIMAB | HEMATOLOGY | PROGRESSION | ANTIGEN
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.